More People With HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study Shows

During HIV Infection, Antibody Can Block B Cells From Fighting Pathogens

High-Risk Youth in Lower-Income Countries Who Inject Drugs: Challenges and Opportunities

Sex and the HIV Reservoir: New Research Points to the Powerful Effect of Estrogen

This Week in HIV Research: Treatment Does a Body Good

Helping Providers Increase Capacity to Care for Patients on PrEP

HIV PrEP in the U.S. Military Services

HIV-Related Stigma and Discrimination: New Insights for Effective Interventions From AIDS 2018

Why Has HIV in Saskatchewan Become More Harmful for Some People?

HIV Prevention and Treatment Strategies for Africa's Growing Teen and Young Adults Are Central to Future World Progress

This Week in HIV Research: Another Notch in the "Treatment as Prevention" Belt

Issues Unrelated to HIV Are Affecting Survival

For Transgender Women, PrEP Is Safe to Use With Estradiol as Feminizing Hormone Therapy, Study Says

Biktarvy in Women With HIV

Lynne Mofenson, M.D., Explains the Dolutegravir Risks for People With HIV Who Want to Get Pregnant

Dolutegravir-Based Two-Drug Regimen Just as Good for HIV Treatment as Three-Drug Therapy, Study Says